{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.1","value":"18.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"WPRE persistence of quantifiable CD19 CAR summarized with mean and standard deviation","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation.\n\nperipheral blood stem cell transplantation (PBSCT): Undergo autologous PBSCT\n\nfilgrastim: Given IV\n\npolymerase chain reaction: Correlative studies\n\nrituximab: Given IV\n\ngenetically engineered lymphocyte therapy: Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR)\n\nlaboratory biomarker analysis: Correlative studies\n\nplerixafor: Given IV\n\nautologous hematopoietic stem cell transplantation: Undergo autologous PBSCT","id":"OG000","title":"Treatment (Cellular Adoptive Immunotherapy Following PBSCT)"}],"paramType":"MEAN","populationDescription":"1 participant in dose level 1 did not have any whole blood samples to analyze. Overall mean was reported due to small samples sizes in each dose level.","reportingStatus":"POSTED","timeFrame":"28 days post T cell infusion","title":"Number of Days of Quantifiable CD19 CAR Post T-cell Infusion","type":"PRIMARY","unitOfMeasure":"days"}